There’s no question that Pfizer, BioNTech, and Moderna are critically important to reduce the risks of covid.
We expect MRNA to benefit in the coming years from strong recurring sales of their COVID-19 vaccines. Moderna president Stephen Hoge recently stated that he thinks “that there’s going to be a chronic booster need.”
We expect that MRNA will be driving an industry-wide consolidation starting as early as 2022 thereby building up their pipelines and potentially making strategic acquisitions.